SMStuart Madden

Stuart Madden

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stuart Madden has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evaluating Bioequivalence of a New, Higher-Concentration Diazepam Nasal Spray for Seizure Clusters Compared with the Current Formulation in Healthy Adults

    by Stuart Madden, Miguel A. Lopez-Toledano, Leock Y. Ngo, Enrique Carrazana, Adrian L. Rabinowicz

    Introduction Diazepam nasal spray is an immediate-use seizure medication for seizure clusters in patients with epilepsy aged ≥ 2 years. Currently, administration of 5- and 10-mg age- and weight-based doses requires a single device, and two devices are needed for the 15- and 20-mg doses (1 spray/nostril). Methods This phase 1, open-label, randomized, 2-sequence, 2-treatment, 3-period crossover study in healthy adults examined whether a single 20-mg diazepam nasal spray actuation of a new formulation with a higher diazepam concentration (test formulation) was bioequivalent to two 10-mg actuations of the current formulation (reference formulation). Participants were randomly assigned to receive the test formulation twice and the reference formulation once or the reference formulation twice and the test formulation once. Safety was assessed. Results Eighty-six participants were assigned 1:1 to each treatment sequence (n = 43 each). The mean plasma diazepam concentration–time profiles following the administration of the test and reference formulations were largely overlapping. Bioequivalence criteria were met for area under the concentration–time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC0–t) and AUC from time 0 extrapolated to infinity (AUC0–∞) but not met for maximum observed plasma concentration (Cmax). Two patients receiving the test formulation had mild coronavirus disease 2019 during the study; there were no treatment-related or serious treatment-emergent adverse events. Conclusions A single 20-mg actuation of diazepam nasal spray was bioequivalent to two 10-mg actuations with respect to AUC0–t and AUC0–∞ but not Cmax. There were no new safety signals for either formulation. The single-actuation formulation may represent a valid and simpler alternative for treatment of seizure clusters.

  • Open Access

    Safety, Tolerability, and Pharmacokinetics of NRL-1049, a Rho-Associated Kinase Inhibitor, in Healthy Volunteers: A Phase 1, First-in-Human, Single-Ascending Dose, Randomized, Placebo-Controlled Trial

    by Stuart Madden, Issam Awad, Miguel A. Lopez-Toledano, Leslie Morrison, Juan Gutierrez, Leock Y. Ngo, Enrique Carrazana, Adrian L. Rabinowicz

    Background and Objectives Cerebral cavernous malformations (CCMs) are vascular lesions of the brain that can lead to hemorrhage, focal neurologic deficits, and seizures. Rho-associated kinase (ROCK) overactivation plays a critical role in the development of CCMs, and a novel, selective ROCK2 inhibitor, NRL-1049, mitigated lesion burden and bleeding in mouse models of CCM. This study examined the safety, tolerability, and pharmacokinetics of NRL-1049 in healthy volunteers. Methods In this first-in-human, randomized, double-blind, single-ascending dose study, participants received a single, oral dose of NRL-1049 (25, 75, 150, or 250 mg) or placebo in a fasted state (period 1). In period 2, participants received 150 mg NRL-1049 or placebo 30 min after a standardized high-fat, high-calorie meal. Blood samples for pharmacokinetic analysis were collected pre-dose and at post-dose time points from 5 min to 48 h. Treatment-emergent adverse events (TEAEs) were recorded and pharmacokinetic parameters determined, including maximum drug concentration (Cmax), time to Cmax (tmax), and area under the concentration-time curve (AUC) from time 0 to last quantifiable concentration (AUC0–t) and extrapolated to infinity (AUC0–∞). Results Of the 24 participants in period 1 who received NRL-1049 (fasted), 9 (37.5%) experienced ≥ 1 TEAE, with 8 (33.3%) reporting ≥ 1 treatment-related TEAE. TEAEs appeared to correlate with dose, and 150 mg was the maximum tolerated dose following single-dose administration in this study. The most common TEAEs (> 5%) were dizziness (16.7%), headache (8.3%), and syncope (8.3%). In period 2 (n = 10), four (40.0%) participants who received 150 mg NRL-1049 (fed) reported ≥ 1 TEAE, and three (30.0%) reported a treatment-related TEAE. There were no reports of serious TEAEs or discontinuations due to a TEAE. NRL-1049 was rapidly absorbed in the fasted state, with median tmax ranging from 0.50 to 0.75 h. Mean Cmax increased over the dose range of 25–250 mg (3.66–58.0 ng/mL). As NRL-1049 dose increased in a ratio of 1:3:6:10, mean Cmax similarly increased (1:5:10:16), while AUC0–t and AUC0–∞ increased in a greater-than-dose proportional manner (1:5:11:25 and 1:4:10:21, respectively; P < 0.001). In the fed state (150 mg NRL-1049), mean Cmax (18.5 ng/mL) was lower compared with the fasted state (34.9 ng/mL). For the active metabolite, NRL-2017, in the fasted state, median tmax was 0.88–1.63 h, and mean Cmax increased over the dose range (54.2–1520 ng/mL). Mean Cmax (1:6:14:28), AUC0–t (1:4:7:14), and AUC0–∞ (1:3:6:13) of NRL-2017 increased in a greater-than-dose proportional manner (P < 0.001). In the fed state, mean Cmax was lower compared with the fasted state. Conclusions The maximum tolerated dose of 150 mg NRL-1049 was associated with a favorable safety profile in healthy adult volunteers. Exposure of NRL-1049 and its active metabolite, NRL-2017, increased in a dose proportional or greater-than-dose proportional manner. These results support continued investigation and development of NRL-1049.


  • A Single-Dose, Randomized, Open-Label, Parallel Design Study to Characterize the Pharmacokinetics of an Investigational Olanzapine Intranasal Spray Compared to a Reference Dose of Olanzapine Intramuscular Injection in Healthy Adult Males

    by Stuart Madden, Leslie Citrome, Christoph U. Correll, Evelyn K. Shih, Miguel Lopez-Toledano, Adrian L. Rabinowicz, Enrique Carrazana

    Two investigational intranasal formulations of olanzapine containing the permeation enhancer dodecyl maltoside showed favorable pharmacokinetics and an acceptable safety profile in healthy adults.


  • Open Access

    Optimizing Absorption for Intranasal Delivery of Drugs Targeting the Central Nervous System Using Alkylsaccharide Permeation Enhancers

    by Stuart Madden, Enrique Carrazana, Adrian L. Rabinowicz

    Intranasal delivery of drugs offers several potential benefits related to ease of delivery, rapid onset, and patient experience, which may be of particular relevance to patients with central nervous system (CNS) conditions who experience acute events. Intranasal formulations must be adapted to address anatomical and physiological characteristics of the nasal cavity, including restricted dose volume, limited surface area, and barriers to mucosal absorption, in addition to constraints on the absorption window due to mucociliary clearance. Development of an effective formulation may utilize strategies including the addition of excipients to address the physicochemical properties of the drug within the constraints of nasal delivery. Dodecyl maltoside (DDM) and tetradecyl maltoside are alkylsaccharide permeation enhancers with well-established safety profiles, and studies have demonstrated transiently improved absorption and favorable bioavailability of several compounds in preclinical and clinical trials. Dodecyl maltoside is a component of three US Food and Drug Administration (FDA)–approved intranasal medications: diazepam for the treatment of seizure cluster in epilepsy, nalmefene for the treatment of acute opioid overdose, and sumatriptan for the treatment of migraine. Another drug product with DDM as an excipient is currently under FDA review, and numerous investigational drugs are in early-stage development. Here, we review factors related to the delivery of intranasal drugs and the role of alkylsaccharide permeation enhancers in the context of approved and future intranasal formulations of drugs for CNS conditions.